Bemcentinib – A selective AXL inhibitor currently in Phase II
Learn MoreLATEST NEWS
BERGENBIO ASA: LEADERSHIP CHANGE
Read moreScientific Presentations
ASV 2021, Mr. Dana Bohan
20th July 2021
Phosphatidylserine Receptors Enhance SARS-CoV-2 Infection: AXL as a Therapeutic Agent for COVID-19
Pipeline of first-in-class AXL inhibitors for the treatment of aggressive diseases.
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone therapy for aggressive diseases, including immune-evasive, therapy resistant cancers, fibrosis and viral infection.
BerGenBio’s lead candidate, bemcentinib, is a once-a-day, oral, highly selective and potent inhibitor of AXL kinase, which has demonstrated a key role in cancer treatment by preventing immune evasion, drug resistance and metastasis in a variety of cancer trials.
Additionally, bemcentinib has been reported to exhibit potent anti-viral activity in preclinical models of infection by enveloped viruses, including Ebola and Zika. Recent data have expanded this to SARS-CoV-2 where findings suggest that bemcentinib stops the virus entering the host cells and neutralising its anti-viral defence mechanisms. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (OSE:BGBIO).
Explore BerGenBio’s pipelineLatest News
BERGENBIO ASA: LEADERSHIP CHANGE
Bergen, Norway, 22 August 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical need, announces the appointment of Martin Olin as new
Read moreBERGENBIO PRESENTS ENCOURAGING UPDATED PRELIMINARY DATA FROM PHASE II STUDY IN RELAPSED AML PATIENTS AT EHA VIRTUAL MEETING
Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML patients Bergen, Norway, 11 June 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical
Read moreBERGENBIO ANNOUNCES LATE-BREAKING ABSTRACT PRESENTATION AT ECCMID 2021
Bergen, Norway, 10 June 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stagebiopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that an analysis
Read moreBERGENBIO RECEIVED FDA FAST-TRACK DESIGNATION FOR BEMCENTINIB / ANTI-PD-(L)1 COMBINATION IN NSCLC
First recognition by a regulator of AXL-positive patients as a target population Bergen, Norway, 08 June 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective
Read more
